Please login to the form below

Not currently logged in
Email:
Password:

Ikervis

This page shows the latest Ikervis news and features for those working in and with pharma, biotech and healthcare.

NICE no for new eye disease drug

NICE no for new eye disease drug

In a statement NICE said that its independent Appraisal Committee had not been presented with evidence on the relative cost and clinical effectiveness of Ikervis compared with established clinical practice. ... It also wants to see an economic model

Latest news

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    The final two drugs to feature in the list of positive opinions were Santen's Ikervis (ciclosporin) for the treatment of the eye condition severe keratitis and MDCO's Raplixa (human

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics